Abcl stock forecast.

10 equities research analysts have issued twelve-month target prices for AbCellera Biologics' stock. Their ABCL share price …Nov 21, 2023 · Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The …Vortex Energy Corp () Stock Market info Recommendations: Buy or sell Vertex Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Vertex Pharmaceuticals's VRTX shares and …ABCL earnings call for the period ending September 30, 2023. Motley Fool Transcribing | Nov 3, 2023 AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript

According to 14 stock analysts, the average 12-month stock price forecast for Palantir stock is $13.25, which predicts a decrease of -34.63%. The lowest target is $5.00 and the highest is $25. On average, analysts rate Palantir stock as a hold.Apple Inc. Common Stock. $191.45 +1.76 +0.93%. Find the latest dividend history for AbCellera Biologics Inc. Common Shares (ABCL) at Nasdaq.com.

In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.

We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.Abcellera Biologics Inc. 4.76. Delayed Data. As of 3:59pm ET. +0.035 / +0.74%. Today’s Change. 3.87. Today ||| 52-Week Range. 14.00. A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Microbot Medical Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median ...Abcellera Biologics Inc (ABCL) Company Description. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

VANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023. Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing.

Nov 7, 2023 · Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -660.63% from its current level, while the stock would need to crash -123.71% from its current level to reach the projected low. 2 days ago · Stock Price Forecast. According to 7 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $23.29, which predicts an increase of 436.64%. The lowest target is $12 and the highest is $32. On average, analysts rate ABCL stock stock as a strong buy. Get the latest stock price for AbCellera Biologics Inc. (ABCL:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings.Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating. ABCL stock forecast for 2023 – 2027. Last updated: October 5, 2023. ABCL. AbCellera Biologics Inc. 4.43 D 1.14% (0.05) Are you interested in AbCellera Biologics Inc. stocks prediction? If yes, then on this page you will find useful information about the dynamics of the ABCL stock price in 2022-2027. Is ABCL a good long term stock? When should ...Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of …Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.Find the latest Institutional Holdings data for AbCellera Biologics Inc. Common Shares (ABCL) at Nasdaq.com.Nov 2, 2023 · AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023. Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Microbot Medical Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median ...

Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.The AbCellera Biologics Inc ( ABCL) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $10.03, representing a …

Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -660.63% from its current level, while the stock would need to crash -123.71% from its current level to reach the projected low.VANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023. Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing.ABCL Forecast 2023. Check the latest forecasts. Read charts, analyst ratings, dividend and earningsFind the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating.According to our research, ABCL stock is a bad long-term investment. ABCL share price has been in a bear cycle for the past year. AbCellera Biologics Inc. …CrowdStrike was founded in 2011 and completed its IPO on June 12, 2019 at $34 per share. About 31% of the company's revenue is generated outside the U.S. Analyst Report: Crowdstrike Holdings Inc ...The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is 10.10 - 35.70 USD. Based on the ratings of 15, the consensus recommendation for ABCL is BUYAnalyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low.

Price Performance Review of ABCL. On Monday, AbCellera Biologics Inc [NASDAQ:ABCL] saw its stock jump 2.91% to $4.60. On the same session, the stock had its day’s lowest price of $4.345, but rose to a high of $4.69. Over the last five days, the stock has gained 15.58%. AbCellera Biologics Inc shares have fallen nearly -54.59% since the year ...

We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.

15 sept 2023 ... ... . ABCELLERA stock analysis ABCELLERA stock news ABCELLERA stock forecast ABCELLERA stock buy or sell ABCELLERA stock investment advice ABCELLERA ...Aditya Birla Cap. share price was Rs 169.90 as on 01 Dec, 2023, 03:59 PM IST. Aditya Birla Cap. share price was up by 1.13% based on previous share price of Rs. 169.15. In last 1 Month, Aditya Birla Cap. share price moved down by 0.12%. 2.Nov 5, 2023 · View 8 reports from 3 analysts offering long term price targets for Aditya Birla Capital Ltd.. Aditya Birla Capital Ltd. has an average target of 205.67. The consensus estimate represents an upside of 21.05% from the last price of 169.90. Reco - This broker has downgraded this stock from it's previous report. In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. There was a ~35% reduction in Q2 2021 at ...AbCellera Biologics Inc. (ABCL 4.21%) Q4 2021 Earnings Call Feb 24, 2022, 5:00 p.m. ET Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Ladies and ...4 ago 2023 ... As of Friday, August 04, AbCellera Biologics Inc's ABCL share price has dipped by 13.34%, which has investors questioning if this is right ...What are the most recommended stocks by analysts? Robyn Karnauskas is a 4.27-star Wall Street Analyst at Truist Financial. Robyn Karnauskas's focuses on the Healthcare sector and covers 71 stocks with a 48.66% success rate.

Complete AbCellera Biologics Inc. stock information by Barron's. View real-time ABCL stock price and news, along with industry-best analysis.Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …Nov 29, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ... Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsInstagram:https://instagram. webull options paper tradingretail etf stockutilities spdr etfmutf vbiax Nov 29, 2023 · According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price. 5 may 2023 ... Invest Now or Wait for the Stock Market to Crash - 2023 Stock Market Update ... AbCellera Stock Analysis | Why ABCL Stock is Falling. Nanalyze•4.6 ... vanguard wesleycommercial gym insurance Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ... what is a 1964 silver half dollar worth Wall Street Stock Market & Finance report, prediction for the future: You'll find the Alphabet Inc Class A share forecasts, stock quote and buy / sell signals below. According to present data Alphabet Inc Class A's GOOGL shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).JYNT. The Joint Corp. 9.24. -0.01. -0.11%. In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap ...